Press Releases
T-Therapeutics to present at the 2026 AACR Annual Meeting
18 March 2026; Cambridge, England – T-Therapeutics, a biotechnology company pioneering next-generation bispecific T-cell receptor (TCR) engagers for oncology and autoimmune disease, will be presenting a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego,…
Read More
T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic
$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England – T-Therapeutics, a…
Read More
T-Therapeutics appoints Theodora Harold as Chief Executive Officer, reflecting Company’s ambitious growth plans and progression into therapeutic development
Theodora has over 25 years’ experience in the biotech sector, with a proven track record of dynamic leadership. 10 March 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble T cell receptor (TCR) therapeutics targeting cancer and autoimmune indications, announces the…
Read More
T-Therapeutics appoints Dr David Hung as Chairman
Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs 12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces…
Read More
